Invasive aspergillosis in the intensive care unit

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Mycology

Background:

• Invasive aspergillosis (IA) incidence in intensive care units (ICUs) is not well-established.
• Risk factors include chronic obstructive pulmonary disease and liver failure, not solely hematological malignancy.
• Current diagnostic methods for IA in ICUs are limited by low sensitivity and specificity.

Purpose of the Study:

• To review the incidence, diagnosis, and treatment of invasive aspergillosis in the ICU.
• To highlight the challenges in diagnosing IA in mechanically ventilated patients.
• To discuss the need for validated diagnostic markers and updated therapeutic data in the ICU setting.

Main Methods:

• Literature review of IA incidence and outcomes in ICU settings.
• Analysis of diagnostic challenges, including interpretation of cultures and imaging.
• Evaluation of current and emerging diagnostic markers like galactomannan.
• Assessment of therapeutic options and data gaps for antifungal agents in ICUs.

Main Results:

• Reported IA incidence in a medical ICU is 5.8%.
• Non-hematological conditions are significant risk factors.
• Diagnostic difficulties arise from mechanical ventilation and underlying lung diseases.
• Positive respiratory cultures have uncertain significance due to variable sensitivity and specificity.
• Delayed diagnosis contributes to a mortality rate exceeding 50%.

Conclusions:

• IA is a significant concern in ICUs, affecting diverse patient populations.
• Improved diagnostic tools, particularly for bronchoalveolar lavage fluid, are crucial.
• Further research is needed on the safety and efficacy of new antifungal agents in the ICU.
• Addressing diagnostic delays is critical to reducing IA-associated mortality.